United States: DIA 2015 Provides Panels On All Types Of FDA-Regulated Products With Many Opportunities For Insight And Interaction – Part Two Of Two

Last Updated: June 25 2015
Article by Brian J. Malkin

This is the second part of coverage of the Drug Information Association (DIA)’ 51st Annual Meeting, held on June 15-18, 2015 in Washington, D.C. For part one, see here.

On the third day, the Center for Biologics Evaluation and Research (CBER) conducted its own Town Hall. CBER Director, Karen Midthun, explained how CBER works proactively to help develop new biological therapies. For example, recognizing the resurgence of whooping cough, caused by B. pertussis, CBER scientist developed a baboon model to help gain insights into vaccine protection. CBER is also working to help understand the causes of the thrombin adverse events associated with the use of immune globulin products. Theresa Finn, Associate Director for Regulatory Policy Office of Vaccines Research and Review (OVRR), CBER, discussed CBER's expedited development programs and potential use of the animal efficacy rule to help with the development of products that cannot be ethically tested in humans. The animal efficacy rule is a rule that I worked on at FDA, which was developed to address the challenges that were presented when it is unethical or not possible to conduct adequate and well-controlled clinical efficacy studies for certain indications, e.g., anthrax, plague, and tularemia.

Wilson Bryan, Director of the Division of Clinical Evaluation and Pharmacology/Toxicology, Office of Cellular, Tissue and Gene Therapy (OCTGT), CBER, explained how CBER helps to facilitate cutting edge research for diseases sometimes previously abandoned by drug development due to the challenges presented or limited patient set. For example, CBER is working with the National Institutes of Health (NIH) to figure out why a T-cell modification thought to help prevent different forms of cancer penetrated the brain and caused various neurological issues. As another example, scientists are working on ways to remove defective mitochondrial DNA from a mother's egg by using donor DNA, which has already been performed in monkeys, which raises its own ethical and social policy issues that go beyond FDA's premarket review and approval. And then Steven Anderson, Director, Office of Biostatistics and Epidemiology, CBER, described ways FDA can utilize statistical techniques to generate new ways to look at data. Anderson here described a statistical study using the Centers for Medicare and Medicaid Services (CMS) data to help evaluate the effectiveness of high-dose influenza vaccine in elderly patients that utilized "big data" to analyze about 30,000 patients, far exceeding the numbers typically in the hundreds for most clinical trials. Anderson further observed that while adaptive clinical trial designs have been supported by CBER in various guidances and touted by others as a way to make clinical trials more efficient and potentially require fewer subjects to demonstrate safety and effectiveness, he found that from looking at studies submitted to CBER from 2008-2014, curiously adaptive clinical trials were very rare (perhaps one or two a year at CBER).

During a question and answer period, the cutting edge nature of the CBER presentations became clear, because a number of the topics discussed were not ready for prime time. For example, CBER cannot use the big data analysis of the large-dose influenza vaccine for regulatory purposes or to add to product labelings yet, because it uses de‑identified subject information, and it is unclear how it will line up with adequate and well-controlled clinical studies—FDA's gold standard. While companies may seek accelerated pathway designations, the CBER experts observed, this does not necessarily mean that the proposed treatment is approved sooner, because a manufacturer / sponsor still needs to seek and take advantage of the opportunities for increased CBER input during the product development process, which does not always occur. But in any event, Midthun noted, CBER manages to keep itself cutting edge by hiring reviewers with knowledge of the cutting edge science and collaborating with other world regulatory agencies.

And yet another cross-cutting session was "Enhanced Collaborative Strategies: FDA and Device Makers Focusing on Improved Devices" that discussed viewpoints from CDRH reviewers and former CDRH reviewers now working for industry, as well as consultants that have worked on a variety of medical device products, including combination products. Potential strategies, such as CDRH's pre-submission program, was discussed by Roshana Ahmed, Senior Manager, Regulatory Affairs, Medical Devices, MAPI. Geeta Pamidimukkala, Biomedical Engineer, CDRH, described CDRH's refusal to accept (RTA) 510(k) process that has improved submission quality and enhanced review efficiencies within CDRH. Along these lines, Pamidimukkala provided tips to prevent an RTA, as well as tips to working with CDRH to help resolve issues and restructure submissions. For example, identifying a good predicate device for a 510(k) is critical, but some applicants include too many predicates in their applications, leading to reviewer confusion or overload, and possibly a mis-step by identifying products that are not really substantially equivalent. Sponsors should respond to RTAs completely, Pamidimukkala suggested, rather than including promissory notes for completion of research/studies that is not included in the response.

During a question and answer period, an interesting question was posed how FDA handles assisting applicants without revealing confidential information from competitors. Here Pamidimukkala noted that FDA is very careful to protect such information to the point where a deficiency may look vague to an applicant. To this end, applicants should ask questions, Pamidimukkala suggested, rather than pursuing a course to correct a deficiency without understanding what information the reviewer(s) were ultimately looking for to support a product clearance or approval.

The fourth day featured additional hot topics such as a new program permitting questions between FDA and the European Medicines Agency (EMA), global development of biologics, the CDER Town Hall, and more. These are just some examples of the variety of programming available at DIA's Annual Meeting this year. As with other DIA Annual Meeting programs, this year's meeting delivered and provided numerous opportunities for attendees to interact and network in productive ways.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions